Association of male lower urinary tract symptoms with metabolic syndrome: a prospective study from tertiary care centre

Vivekanand Hiremath; Anupam Choudhary; Pawan Kumar S. K.; Arun Chawla; Padmaraj Hedge; Akanchha

doi:10.18203/2320-6012.ijrms20242208

Authors

Vivekanand Hiremath Department of Urology, St johns Medical College Hospital, Bangalore, Karnataka, India https://orcid.org/0000-0001-9114-2255
Anupam Choudhary Department of Urology, Kasturba Medical College Hospital, Manipal, Udupi, Karnataka, India
Pawan Kumar S. K. Department of Urology, St johns Medical College Hospital, Bangalore, Karnataka, India
Arun Chawla Department of Urology, Kasturba Medical College Hospital, Manipal, Udupi, Karnataka, India
Padmaraj Hedge Department of Urology, Kasturba Medical College Hospital, Manipal, Udupi, Karnataka, India
Akanchha Department of Pathology, PES Medical College Electronic City, Bangalore, Karnataka, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20242208

Keywords:

IIEF, IPSS, Lower urinary tract symptoms, Metabolic syndrome, Prostate volume

Abstract

Background: The exact nature of the association between metabolic syndrome (MetS) and lower urinary tract symptoms (LUTS) is still not completely understood. There appears to be support for the hypothesis that metabolic and pathological derangements characterizing MetS can promote the development and progression of Benign Prostatic Enlargement and LUTS.

Methods: A total of 212 patients were included in the study, of whom 106 (50%) had LUTS and metabolic syndrome and 106 (50%) had LUTS without metabolic syndrome. The severity of the patient’s lower urinary tract symptoms was assessed by the International Prostate Symptom Score (IPSS). Erectile function was assessed by a 5 question International Index of Erectile Function (IIEF) Questionnaire. MetS was defined according to the National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATPIII).

Results: The study showed a statistically significant association between prostate volume, IPSS score, and each individual component of metabolic syndrome. There is a significant association between metabolic syndrome and sexual dysfunction in men, and the severity of lower urinary tract symptoms is correlated with the severity of erectile dysfunction in the age group in the department of urology.

Conclusions: Patients with MetS, characterized by increased waist circumference, BMI, triglycerides, and decreased HDL levels, exhibited more severe Lower urinary tract symptoms, along with heightened sexual dysfunction, particularly erectile and ejaculatory dysfunction.

Metrics

Metrics Loading ...

References

De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK. The correlation between metabolic syndrome and prostatic diseases. Eur urol. 2012;61(3):560-70.

Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. Urol J. 2002;168(2):599-604.

Sebastianelli A, Gacci M. Current status of the relationship between metabolic syndrome and lower urinary tract symptoms. Eur Urol Focus. 2018;4(1):25-7.

Vignozzi L. Rastrelli G: Corona G. Benign prostatic hyperplasia: a new metabolic disease?J Endocrinol Invest. 2014;37:313-22.

Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, O’Leary MP, Puppo P, Robertson C, Giuliano F. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur urol. 2003;44(6):637-49.

Parsons JK, Kashefi C: Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. Eur Urol. 2008;53:1228-35.

F. Abdollah, A. Briganti, N. Suardi : Metabolic syndrome and benign prostatic hyperplasia: evidence of a potential relationship, hypothesized etiology, and prevention. Korean J of Urol. 2011;52:507-516.

Kyprianou N, Tu H, Jacobs SC: Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Human pathology. 1996;1:668-75.

Cosimo De Nunzio, Luca Cindolo, Mauro Gacci et.al: Metabolic syndrome and lower urinary tract symptoms in patients with benign prostatic enlargement: a possible link to storage symptoms. 2014;84:1182-7.

Gacci M, Corona G, Vignozzi L. Metabolic syndrome and benign prostatic enlargement: a systematic review and meta‐analysis. BJU International. 2015;115:24-31.

Parsons JK, Carter HB, Partin AW: Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab. 2006;91:2562-8.

Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW: Body size and serum levels of insulin and leptin in urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol. 2003;157:906.

Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D: Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 1998;1:157-62.

Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A: The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urol. 1997;49:822-30.

Diokno AC, Brown MB, Herzog AR: Sexual function in the elderly. Archives of Internal Medicine. 1990;150:197-200.